Natural Products as a Source of Inspiration for Novel Inhibitors of Advanced Glycation Endproducts (AGEs) Formation^{[ # ]}

 

 Artikel einzeln kaufen Lizenzen und Reprints

Abstract

Protein glycation, a post-translational modification found in biological systems, is often associated with a core defect in glucose metabolism. In particular, advanced glycation endproducts are complex heterogeneous sugar-derived protein modifications implicated in the progression of pathological conditions such as atherosclerosis, diabetic complications, skin diseases, rheumatism, hypertension, and neurodegenerative diseases. Undoubtedly, there is the need to expand the knowledge about antiglycation agents that can offer a therapeutic approach in preventing and treating health issues of high social and economic importance. Although various compounds have been under consideration, little data from clinical trials are available, and there is a lack of approved and registered antiglycation agents. Next to the search for novel synthetic advanced glycation endproduct inhibitors, more and more the efforts of scientists are focusing on researching antiglycation compounds from natural origin. The main purpose of this review is to provide a thorough overview of the state of scientific knowledge in the field of natural products from plant origin (e.g., extracts and pure compounds) as inhibitors of advanced glycation endproduct formation in the period between 1990 and 2019. Moreover, the objectives of the summary also include basic chemistry of AGEs formation and classification, pathophysiological significance of AGEs, mechanisms for inhibiting AGEs formation, and examples of several synthetic anti-AGEs drugs.

^# Dedicated to Professor Arnold Vlietinck on the occasion of his 80th birthday.

Publikationsverlauf

Eingereicht: 23. Dezember 2020

Angenommen nach Revision: 10. Juni 2021

Artikel online veröffentlicht:
02. August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Dregan A, Charlton J, Chowienczyk P, Gulliford M. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837-844
  CrossrefPubMedGoogle Scholar
• 2 van der Leeuw J, Beulens J, van Dieren S, Schalkwijk C, Glatz J, Hofker M, Verschuren M, Boer J, van der Graaf Y, Visseren F, Peelen L, van der Schouw Y. Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc 2016; 5: 1-11
  CrossrefPubMedGoogle Scholar
• 3 Thornalley P. The clinical significance of glycation. Clin Lab 1999; 45: 263-273
  PubMedGoogle Scholar
• 4 Fishman S, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med 2018; 24: 1-12
  CrossrefPubMedGoogle Scholar
• 5 Goh SY, Cooper M. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152
  CrossrefPubMedGoogle Scholar
• 6 Rabbani N, Thornalley P. Glycation research in amino acids: a place to call home. Amino Acids 2012; 42: 1087-1096
  CrossrefPubMedGoogle Scholar
• 7 Scheijen J, van de Waarenburg M, Stehouwer C, Schalkwijk C. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Anal Technol Biomed Life Sci 2009; 877: 610-614
  CrossrefPubMedGoogle Scholar
• 8 Stitt A. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85: 746-753
  CrossrefPubMedGoogle Scholar
• 9 Nedić O, Rattan S, Grune T, Trougakos I. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res 2013; 47: 28-38
  CrossrefPubMedGoogle Scholar
• 10 Iannuzzi C, Irace G, Sirangelo I, Williams T. Differential effects of glycation on protein aggregation and amyloid formation. Mol Biosci 2014; 1: 1-8
  PubMedGoogle Scholar
• 11 Niwa T. Dicarbonyls (Glyoxal, Methylglyoxal, and 3-Deoxyglucosone). In: Nibbering D, Desiderio N. eds. Uremic Toxins. Hoboken: Wiley; 2012: 177-192
  CrossrefGoogle Scholar
• 12 Machiels D, Istasse L. La réaction de Maillard: importance et applications en chimie des aliments. Ann Med Vet 2002; 146: 347-352
  PubMedGoogle Scholar
• 13 Thornalley P, Langborg A, Minhas H. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 2015; 344: 109-116
  CrossrefPubMedGoogle Scholar
• 14 Yaylayan V, Huyqhues-Despointes A. Chemistry of Amadori rearrangement products: analysis, synthesis, kinetics, reactions, and spectroscopic properties. Crit Rev Food Sci Nutr 1994; 34: 321-369
  CrossrefPubMedGoogle Scholar
• 15 Namiki M, Hayashu T. New mechanism of the Maillard reaction free radical involving sugar fragmentation and formation. Mail React Foods Nutr 1983; 26: 21-46
  CrossrefPubMedGoogle Scholar
• 16 Wolff S, Dean R. Glucose autoxidation and protein modification. The potential role of ʼautoxidative glycosylationʼ in diabetes. Biochem J 1987; 245: 243-250
  CrossrefPubMedGoogle Scholar
• 17 Wolff S, Jiang Z, Hunt J. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991; 10: 339-352
  CrossrefPubMedGoogle Scholar
• 18 Ahmed N. Advanced glycation endproducts–role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21
  CrossrefPubMedGoogle Scholar
• 19 Miura J, Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications 2003; 17: 16-21
  CrossrefPubMedGoogle Scholar
• 20 Gkogkolou P, Böhm M. Advanced glycation end products: key players in skin aging?. Dermatoendocrinol 2012; 4: 259-270
  CrossrefPubMedGoogle Scholar
• 21 Frye E, Degenhardt T, Thorpe S, Baynes J. Role of the Maillard reaction in aging of tissue proteins: advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998; 273: 18714-18719
  CrossrefPubMedGoogle Scholar
• 22 Sell D, Monnier V. End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 1990; 85: 380-384
  CrossrefPubMedGoogle Scholar
• 23 Wautier M, Massin P, Guillausseau P, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautiere J. N-(carboxymethyl)-lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003; 29: 44-52
  CrossrefPubMedGoogle Scholar
• 24 Wells-Knecht K, Brinkmann E, Wells-Knecht M, Litchfield J, Ahmed M, Reddy S, Zyzak D, Thorpe S, Baynes J. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996; 11: 41-47
  CrossrefPubMedGoogle Scholar
• 25 Fournet M, Bonté F, Desmoulière A. Glycation damage: a possible hub for major pathophysiological disorders and aging. Aging Dis 2018; 9: 880-900
  CrossrefPubMedGoogle Scholar
• 26 Wu C, Huang S, Lin J, Yen G. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct 2011; 2: 224-234
  CrossrefPubMedGoogle Scholar
• 27 Dyer D, Dunn J, Thorpe S, Bailie K, Lyons T, Mccance D, Baynes J. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91: 2463-2469
  CrossrefPubMedGoogle Scholar
• 28 Engelen L, Stehouwer C, Schalkwijk C. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes. Obes Metab 2013; 15: 677-689
  CrossrefPubMedGoogle Scholar
• 29 Moldogazieva N, Mokhosoev I, MelʼNikova T, Porozov Y, Terentiev A. Oxidative stress and advanced lipoxidation and glycation endproducts (ALEs and AGEs) in aging and age-related diseases. Oxid Med Cell Longev 2019; 2019: 1-14
  CrossrefPubMedGoogle Scholar
• 30 Lyons T, Jenkins A. Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Rev 1997; 5: 365-391
  PubMedGoogle Scholar
• 31 Ramasamy R, Vannucci S, Yan S, Herold K, Yan S, Schmidt A. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005; 15: 16-28
  CrossrefPubMedGoogle Scholar
• 32 Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation endproducts and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5: 194-222
  CrossrefPubMedGoogle Scholar
• 33 Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol 2014; 2: 411-429
  CrossrefPubMedGoogle Scholar
• 34 Barbezier N, Tessier F, Chango A. Le récepteur des produits de glycation avancée RAGE/AGER: une vue intégrative pour des applications en clinique. Ann Biol Clin (Paris) 2014; 72: 669-680
  PubMedGoogle Scholar
• 35 Younessi P, Yoonessi A. Advanced glycation endproducts and their receptor-mediated roles: inflammation and oxidative stress. Iran J Med Sci 2011; 36: 154-166
  PubMedGoogle Scholar
• 36 Yamagishi S, Nakamura N, Matsui T. Glycation and cardiovascular disease in diabetes: a perspective on the concept of metabolic memory. J Diabetes 2017; 9: 141-148
  CrossrefPubMedGoogle Scholar
• 37 Cade T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008; 88: 1322-1335
  CrossrefPubMedGoogle Scholar
• 38 Yamagishi S, Nakamura K, Matsui T. Advanced glycation endproducts (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol 2006; 3: 83-88
  CrossrefPubMedGoogle Scholar
• 39 Horiuchi S, Imai N, Ueno M, Kawashima S, Miyakawa Y, Suzuki Y, Nakamaru T, Karasawa R, Araki N, Shimada H, Gejyo F, Arakawa M, Nishi S. Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy. Nephron 2008; 76: 153-160
  PubMedGoogle Scholar
• 40 Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley P. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120
  CrossrefPubMedGoogle Scholar
• 41 Bohlender J, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol – Ren Physiol 2005; 289: 645-659
  CrossrefPubMedGoogle Scholar
• 42 Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol 2017; 16: 1-12
  CrossrefPubMedGoogle Scholar
• 43 Van Putte L, De Schrijver S, Moortgat P. The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: a systematic review. Scars Burn Heal 2016; 2: 1-14
  PubMedGoogle Scholar
• 44 Sasaki N, Fukatsu R, Tsuzuki K, Hayashi Y, Yoshida T, Fujii N, Koike T, Wakayama I, Yanagihara R, Garruto R, Amano N, Makita Z. Advanced glycation end products in Alzheimerʼs disease and other neurodegenerative diseases. Am J Pathol 1998; 153: 1149-1155
  CrossrefPubMedGoogle Scholar
• 45 Peng X, Ma J, Chen F, Wang M. Naturally occurring inhibitors against the formation of advanced glycation end-products. Food Funct 2011; 2: 289-301
  CrossrefPubMedGoogle Scholar
• 46 Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol 2006; 54: 405-419
  CrossrefPubMedGoogle Scholar
• 47 Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J Agric Food Chem 2005; 53: 3167-3173
  CrossrefPubMedGoogle Scholar
• 48 Younus H, Anwar S. Prevention of non-enzymatic glycosylation (glycation): implication in the treatment of diabetic complication. Int J Health Sci (Qassim) 2016; 10: 247-263
  PubMedGoogle Scholar
• 49 Poitevin P, Levy B, Wolffenbuttel B, Boulanger C, Egan J, Vasan S, Ulrich P, Swennen G, Huijberts M, Crijns F, Cerami A. Breakers of advanced glycation endproducts restore large artery properties in experimental diabetes. Proc Natl Acad Sci 1998; 95: 4630-4634
  CrossrefPubMedGoogle Scholar
• 50 Odjakova M, Popova E, Sharif M, Mironova R. Plant-derived Agents with anti-glycation Activity. In: Petrescu S. ed. Glycosylation. London: Intech Open Science; 2011. 64. 223-256
  Google Scholar
• 51 Booth A, Khalifah R, Hudson B. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine 1. Biochem Biophys Res Commun 1996; 220: 113-119
  CrossrefPubMedGoogle Scholar
• 52 Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006; 11: 646-654
  CrossrefPubMedGoogle Scholar
• 53 Thilavech T, Ngamukote S, Abeywardena M, Adisakwattana S. Protective effects of cyanidin-3-rutinoside against monosaccharides-induced protein glycation and oxidation. Int J Biol Macromol 2015; 75: 515-520
  CrossrefPubMedGoogle Scholar
• 54 Khangholi S, Majid F, Berwary N, Ahmad F, Aziz R. The mechanisms of inhibition of advanced glycation end products formation through polyphenols in hyperglycemic condition. Planta Med 2015; 82: 32-45
  Artikel in Thieme ConnectPubMedGoogle Scholar
• 55 Kaewnarin K, Niamsup H, Shank L, Rakariyatham N. Antioxidant and antiglycation activities of some edible and medicinal plants. Chiang Mai J Sci 2014; 41: 105-116
  PubMedGoogle Scholar
• 56 Atanasov A, Waltenberger B, Pferschy-Wenzig E, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss E, Rollinger J, Schuster D, Breuss J, Bochkov V, Mihovilovic M, Kopp B, Bauer R, Dirsch V, Stuppner H. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv 2015; 33: 1582-1614
  CrossrefPubMedGoogle Scholar
• 57 Tsuji-Naito K, Saeki H, Hamano M. Inhibitory effects of Chrysanthemum species extracts on formation of advanced glycation end products. Food Chem 2009; 116: 854-859
  CrossrefPubMedGoogle Scholar
• 58 Jang D, Yoo N, Kim N, Lee Y, Kim C, Kim J, Kim J, Kim J. 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis. Biol Pharm Bull 2010; 33: 329-333
  CrossrefPubMedGoogle Scholar
• 59 Kim H, Kim K. Protein glycation inhibitory and antioxidative activities of some plant extracts in vitro . J Agric Food Chem 2003; 51: 1586-1591
  CrossrefPubMedGoogle Scholar
• 60 Bains Y, Gugliucci A. Ilex paraguariensis and its main component chlorogenic acid inhibit fructose formation of advanced glycation endproducts with amino acids at conditions compatible with those in the digestive system. Fitoterapia 2017; 117: 6-10
  CrossrefPubMedGoogle Scholar
• 61 Ou J, Huang J, Wang M, Ou S. Effect of rosmarinic acid and carnosic acid on AGEs formation in vitro . Food Chem 2017; 221: 1057-1061
  CrossrefPubMedGoogle Scholar
• 62 Ramlagan P, Rondeau P, Planesse C, Neergheen-Bhujun V, Bourdon E, Bahorun T. Comparative suppressing effects of black and green teas on the formation of advanced glycation end products (AGEs) and AGE-induced oxidative stress. Food Funct 2017; 8: 4194-4209
  CrossrefPubMedGoogle Scholar
• 63 Ohno RI, Moroishi N, Nagai M, Nagai R. Mangosteen pericarp extract inhibits the formation of pentosidine and ameliorates skin elasticity. J Clin Biochem Nutr 2015; 57: 27-32
  CrossrefPubMedGoogle Scholar
• 64 Perez Gutierrez RM. Inhibition of advanced glycation endproduct formation by Origanum majorana L. in vitro and in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med 2012; 2012: 1-8
  CrossrefPubMedGoogle Scholar
• 65 Morimitsu Y, Yoshida K, Hirota A, Esaki S. Protein glycation inhibitors from thyme (Thymus vulgaris). Biosci Biotechnol Biochem 1995; 59: 2018-2021
  CrossrefPubMedGoogle Scholar
• 66 Xi M, Hai C, Tang H, Chen M, Fang K, Liang X. Antioxidant and antiglycation properties of total saponins extracted from Traditional Chinese Medicine used to treat diabetes mellitus. Phyther Res 2008; 22: 544-549
  PubMedGoogle Scholar
• 67 Zhang Y, Ma H, Liu W, Yuan T, Seeram N. New antiglycative compounds from cumin (Cuminum cyminum) spice. J Agric Food Chem 2015; 63: 10097-10102
  CrossrefPubMedGoogle Scholar
• 68 Mizutani K, Ikeda K, Yamori Y. Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem Biophys Res Commun 2000; 274: 61-67
  CrossrefPubMedGoogle Scholar
• 69 Sajithlal G, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 1998; 56: 1607-1614
  CrossrefPubMedGoogle Scholar
• 70 Hu T, Liu C, Chyau C, Hu M. Trapping of methylglyoxal by curcumin in cell-free systems and in human umbilical vein endothelial cells. J Agric Food Chem 2012; 60: 8190-8196
  CrossrefPubMedGoogle Scholar
• 71 Alizadeh M, Kheirouri S. Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents. Crit Rev Food Sci Nutr 2019; 59: 1169-1177
  CrossrefPubMedGoogle Scholar
• 72 Varelis P, Melton L, Shahidi F. Encyclopedia of Food Chemistry. Amsterdam: Elsevier; 2019
  Google Scholar
• 73 Park C, Noh J, Tanaka T, Roh S, Lee J, Yokozawa T. Polyphenol isolated from Corni Fructus, 7-O-galloyl-d-sedoheptulose, modulates advanced glycation endproduct-related pathway in type 2 diabetic db/db mice. Arch Pharm Res 2015; 38: 1270-1280
  CrossrefPubMedGoogle Scholar
• 74 Upadhyay A, Tuenter E, Exarchou V, Apers S, Pieters L. Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors. Planta Med 2014; 80: 1001-1008
  Artikel in Thieme ConnectPubMedGoogle Scholar
• 75 Hou J, Zheng D, Fung G, Deng H, Chen L, Liang J, Jiang Y, Hu Y. Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats. Can J Physiol Pharmacol 2016; 94: 1-22
  CrossrefPubMedGoogle Scholar
• 76 Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. Bioorganic Med Chem 2003; 11: 5317-5323
  CrossrefPubMedGoogle Scholar
• 77 Wu Q, Li S, Li X, Fu X, Sui Y, Guo T, Xie B, Sun Z. A significant inhibitory effect on advanced glycation end product formation by catechin as the major metabolite of lotus seedpod oligomeric procyanidins. Nutrients 2014; 6: 3230-3244
  CrossrefPubMedGoogle Scholar
• 78 Matsuura N, Aradate T, Kurosaka C, Ubukata M, Kittaka S, Nakaminami Y, Gamo K, Kojima H, Ohara M. Potent protein glycation inhibition of plantagoside in Plantago major seeds. BioMed 2014; 2014: 1-5
  PubMedGoogle Scholar
• 79 Yang B, Choi E, Shim S. Inhibitory activities of kaempferol against methylglyoxal formation, intermediate of advanced glycation end products. Appl Biol Chem 2017; 60: 57-62
  CrossrefPubMedGoogle Scholar
• 80 Bhuiyan M, Mitsuhashi S, Sigetomi K, Ubukata M. Quercetin inhibits advanced glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species. Biosci Biotechnol Biochem 2017; 81: 882-890
  CrossrefPubMedGoogle Scholar
• 81 Ashraf J, Shahab U, Tabrez S, Lee E, Choi I, Ahmad S. Quercetin as a finer substitute to aminoguanidine in the inhibition of glycation products. Int J Biol Macromol 2015; 77: 188-192
  CrossrefPubMedGoogle Scholar
• 82 Upadhyay A, Tuenter E, Amin A, Exarchou V, Hermans N, Apers S, Pieters L. 5-O-Demethylnobiletin, a polymethoxylated flavonoid, from Citrus depressa Hayata peel prevents protein glycation. J Funct Foods 2014; 11: 243-249
  CrossrefPubMedGoogle Scholar
• 83 Ferchichi L, Derbré S, Mahmood K, Touré K, Guilet D, Litaudon M, Awang K, Hadi A, Le Ray AM, Richomme P. Bioguided fractionation and isolation of natural inhibitors of advanced glycation end-products (AGEs) from Calophyllum flavoramulum . Phytochemistry 2012; 78: 98-106
  CrossrefPubMedGoogle Scholar
• 84 Cheng H, Ton S, Abdul Kadir K. Ellagitannin geraniin: a review of the natural sources, biosynthesis, pharmacokinetics and biological effects. Phytochem Rev 2017; 16: 159-193
  CrossrefPubMedGoogle Scholar
• 85 Xi M, Hai C, Tang H, Wen A, Chen H, Liu R, Liang X, Chen M. Antioxidant and antiglycation properties of triterpenoid saponins from Aralia taibaiensis traditionally used for treating diabetes mellitus. Redox Rep 2010; 15: 20-28
  CrossrefPubMedGoogle Scholar
• 86 Derbré S, Gatto J, Pelleray A, Coulon L, Séraphin D, Richomme P. Automating a 96-well microtiter plate assay for identification of AGEs inhibitors or inducers: application to the screening of a small natural compounds library. Anal Bioanal Chem 2010; 398: 1747-1758
  CrossrefPubMedGoogle Scholar
• 87 Tang Y, Hu C, Sang S. Characterization of reaction products and mechanisms between serotonin and methylglyoxal in model reactions and mice. J Agric Food Chem 2020; 68: 2437-2444
  CrossrefPubMedGoogle Scholar
• 88 Rabbani N, Shaheen F, Anwar A, Masania J, Thornalley P. Assay of methylglyoxal-derived protein and nucleotide AGEs. Biochem Soc Trans 2014; 42: 511-517
  CrossrefPubMedGoogle Scholar
• 89 Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler J. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77
  CrossrefPubMedGoogle Scholar
• 90 Hanssen N, Engelen L, Ferreira I, Scheijen J, Huijberts M, Van Greevenbroek M, van der Kallen C, Dekker J, Nijpels G, Stehouwer C, Schalkwijk C. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl) lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab 2013; 98: 1369-1373
  CrossrefPubMedGoogle Scholar
• 91 Rahbar S, Figarola J. Inhibitors and breakers of advanced glycation endproducts (AGEs): A review. Curr Med Chem Endocr Metab Agents 2002; 2: 135-161
  PubMedGoogle Scholar
• 92 Monnier V. Intervention against the Maillard reaction in vivo . Arch Biochem Biophys 2003; 419: 1-15
  CrossrefPubMedGoogle Scholar
• 93 Odani H, Shinzato T, Usami J, Matsumoto Y, Frye E, Baynes J, Maeda K. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: evidence for increased oxidative stress in uremia. FEBS Lett 1998; 427: 381-385
  CrossrefPubMedGoogle Scholar
• 94 Nakamura K, Nakazawa Y, Ienaga K. Acid-stable fluorescent advanced glycation end products: vesperlysines A, B, and C are formed as crosslinked products in the maillard reaction between lysine or proteins with glucose. Biochem Biophys Res Commun 1997; 232: 227-230
  CrossrefPubMedGoogle Scholar
• 95 Brownlee M, Vlassara H. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Sci New Ser 1986; 232: 1629-1632
  PubMedGoogle Scholar
• 96 Thornalley P, Yurek-George A, Argirov O. Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000; 60: 55-65
  CrossrefPubMedGoogle Scholar
• 97 Borg D, Forbes J. Targeting advanced glycation with pharmaceutical agents: where are we now?. Glycoconj J 2016; 33: 653-670
  CrossrefPubMedGoogle Scholar
• 98 Nagai R, Murray D, Metz T, Baynes J. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012; 61: 549-559
  CrossrefPubMedGoogle Scholar
• 99 Sadowska-Bartosz I, Bartosz G. Prevention of protein glycation by natural compounds. Molecules 2015; 20: 3309-3334
  CrossrefPubMedGoogle Scholar
• 100 Khalifah R, Voziyan P, Serianni A, Jacob J, Thibaudeau C, Yildiz A, Hudson B. Modification of proteins in vitro by physiological levels of glucose. J Biol Chem 2003; 278: 46616-46624
  CrossrefPubMedGoogle Scholar
• 101 Nagaraj R, Sarkar P, Mally A, Biemel K, Lederer M, Padayatti P. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 2002; 402: 110-119
  CrossrefPubMedGoogle Scholar
• 102 Pagnozzi F, Bena E, Beltramo E, Molinatti P, Molinatti G, Porta M, Selva M. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation endproducts in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 2002; 39: 1263-1268
  PubMedGoogle Scholar
• 103 Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, Hotta N. Epalrestat, an aldose reductase inhibitor, reduces the levels of N(ε)-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539-1544
  CrossrefPubMedGoogle Scholar
• 104 Touchette A, Szwergold B, Lal S, Beisswenger P, Howell S. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202
  CrossrefPubMedGoogle Scholar
• 105 Daniel R, Lecomte M, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58: 1765-1773
  CrossrefPubMedGoogle Scholar
• 106 Miyata T, Van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487
  CrossrefPubMedGoogle Scholar
• 107 Forbes J, Cooper M, Thallas V, Burns W, Thomas M, Brammar G, Lee F, Grant S, Burrell L, Jerums G, Osicka T. Reduction of the accumulation of advanced glycation endproducts by ACE inhibition in experimental diabetic nephropathy. Blood Press 2002; 51: 3274-3282
  PubMedGoogle Scholar
• 108 May J, Qu Z. Troglitazone protects human erythrocytes from oxidant damage. Antioxidants Redox Signal 2000; 2: 243-250
  CrossrefPubMedGoogle Scholar
• 109 Chompoo J, Upadhyay A, Kishimoto W, Makise T, Tawata S. Advanced glycation end products inhibitors from Alpinia zerumbet rhizomes. Food Chem 2011; 129: 709-715
  CrossrefPubMedGoogle Scholar
• 110 Li C, Tan F, Yang J, Yang Y, Gou Y, Li S, Zhao X. Antioxidant effects of Apocynum venetum tea extracts on D-Galactose-induced aging model in mice. Antioxidants 2019; 8: 1-16
  CrossrefPubMedGoogle Scholar
• 111 Yokozawa T, Nakagawa T. Inhibitory effects of Luobuma tea and its components against glucose-mediated protein damage. Food Chem Toxicol 2004; 42: 975-981
  CrossrefPubMedGoogle Scholar
• 112 Motomura K, Fujiwara Y, Kiyota N, Tsurushima K, Takeya M, Nohara T, Nagai R, Ikeda T. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products. J Agric Food Chem 2009; 57: 7666-7672
  CrossrefPubMedGoogle Scholar
• 113 Ahmad H, Khan I, Wahid A. Antiglycation and antioxidation properties of Juglans regia and Calendula officinalis: possible role in reducing diabetic complications and slowing down ageing. J Tradit Chinese Med 2012; 32: 411-414
  CrossrefPubMedGoogle Scholar
• 114 Shakthi A, Sathish T, Kumaresan K, Rapheal V. Extraction process optimization of polyphenols from Indian Citrus sinensis as novel antiglycative agents in the management of diabetes mellitus. J Diabetes Metab Disord 2014; 13: 1-10
  CrossrefPubMedGoogle Scholar
• 115 Ramful D, Tarnus E, Rondeau P, Da Silva C, Bahorun T, Bourdon E. Citrus fruit extracts reduce advanced glycation end products (AGEs)- and H2O2-induced oxidative stress in human adipocytes. J Agric Food Chem 2010; 58: 11119-11129
  CrossrefPubMedGoogle Scholar
• 116 Liu J, Feng L, Zhu M, Wang R, Zhang M, Hu S, Jia X, Wu J. The in vitro protective effects of curcumin and demethoxycurcumin in Curcuma longa extract on advanced glycation end products-induced mesangial cell apoptosis and oxidative stress. Planta Med 2012; 78: 1757-1760
  Artikel in Thieme ConnectPubMedGoogle Scholar
• 117 Adaramoye O, Anjos R, Almeida M, Veras R, Silvia D, Oliveira F, Cavalcante K, Araújo I, Oliveira A, Medeiros I. Hypotensive and endothelium-independent vasorelaxant effects of methanolic extract from Curcuma longa L. in rats. J Ethnopharmacol 2009; 124: 457-462
  CrossrefPubMedGoogle Scholar
• 118 Harris C, Cuerrier A, Lamont E, Haddad P, Arnason J, Bennett S, Johns T. Investigating wild berries as a dietary approach to reducing the formation of advanced glycation endproducts: chemical correlates of in vitro antiglycation activity. Plant Foods Hum Nutr 2014; 69: 71-77
  CrossrefPubMedGoogle Scholar
• 119 Siddiqui M, Rasheed S, Saquib Q, Al-Khedhairy A, Al-Said M, Musarrat J, Choudhary M. In vitro dual inhibition of prontein glycation, and oxidation by some Arabian plants. BMC Complement Altern Med 2016; 16: 1-11
  CrossrefPubMedGoogle Scholar
• 120 Abbas G, Hassan M, Saddiqe Z, Shahzad M. Non-toxic fractions of Hypericum perforatum and Hypericum oblongifolium inhibit protein glycation, free radicals production and lipid peroxidation in vitro . Int J Phytomedicine 2013; 5: 191-196
  PubMedGoogle Scholar
• 121 Yoo N, Jang D, Lee Y, Jeong I, Cho J, Kim J, Kim J. Anthraquinones from the roots of Knoxia valerianoides inhibit the formation of advanced glycation end products and rat lens aldose reductase in vitro . Arch Pharm Res 2010; 33: 209-214
  CrossrefPubMedGoogle Scholar
• 122 Hwang S, Wang Z, Quispe Y, Lim S, Yu J. Evaluation of aldose reductase, protein glycation, and antioxidant inhibitory activities of bioactive flavonoids in Matricaria recutita L. and their structure-activity relationship. J Diabetes Res 2018; 2018: 1-11
  CrossrefPubMedGoogle Scholar
• 123 Yui S, Fujiwara S, Harada K, Motoike-Hamura M, Sakai M, Matsubara S, Miyazaki K. Beneficial effects of lemon balm leaf extract on in vitro glycation of proteins, arterial stiffness, and skin elasticity in healthy adults. J Nutr Sci Vitaminol (Tokyo) 2017; 63: 59-68
  CrossrefPubMedGoogle Scholar
• 124 Tupe R, Sankhe N, Shaikh S, Kemse N, Khaire A, Phatak D, Parikh J. Nutraceutical properties of dietary plants extracts: Prevention of diabetic nephropathy through inhibition of glycation and toxicity to erythrocytes and HEK293 cells. Pharm Biol 2015; 53: 40-50
  CrossrefPubMedGoogle Scholar
• 125 Pandey R, Kumar D, Ali A. Nigella sativa seed extracts prevent the glycation of protein and DNA. Curr Perspect Med Aromat Plants 2018; 1: 1-7
  PubMedGoogle Scholar
• 126 Chen W, Balan P, Popovich D. Review of ginseng anti-diabetic studies. Molecules 2019; 24: 1-16
  CrossrefPubMedGoogle Scholar
• 127 Lv L, Cheng Y, Zheng T, Li X, Zhai R. Purification, antioxidant activity and anti-glycation of polysaccharides from Polygonum multiflorum Thunb. Carbohydr Polym 2014; 99: 765-773
  CrossrefPubMedGoogle Scholar
• 128 Kumagai Y, Nakatani S, Onodera H, Nagatomo A, Nishida N, Matsuura Y, Kobata K, Wada M. Anti-glycation effects of pomegranate (Punica granatum L.) fruit extract and its components in vivo and in vitro . J Agric Food Chem 2015; 63: 7760-7764
  CrossrefPubMedGoogle Scholar
• 129 Di Sotto A, Locatelli M, Macone A, Toniolo C, Cesa S, Carradori S, Eufemi M, Mazzanti G, Di Giacomo S. Hypoglycemic, antiglycation, and cytoprotective properties of a phenol-rich extract from waste peel of Punica granatum L. Var. Dente di cavallo DC2. Molecules 2019; 24: 1-22
  CrossrefPubMedGoogle Scholar
• 130 Lee E, Song D, Lee J, Pan C, Um B, Jung S. Inhibitory effect of the compounds isolated from Rhus verniciflua on aldose reductase and advanced glycation endproducts. Biol Pharm Bull 2008; 31: 1626-1630
  CrossrefPubMedGoogle Scholar
• 131 Kiho T, Usui S, Hirano K, Aizawa K, Inakuma T. Tomato paste fraction inhibiting the formation of advanced glycation end-products. Biosci Biotechnol Biochem 2004; 68: 200-205
  CrossrefPubMedGoogle Scholar
• 132 Abeysekera W. Anti-glycation and glycation reversing potential of fenugreek (Trigonella foenum-graecum) seed extract. Biomed J Sci Tech Res 2018; 3: 3138-3142
  PubMedGoogle Scholar
• 133 Ferrier J, Djeffal S, Morgan H, van der Kloet S, Redžić S, Cuerrier A, Balick M, Arnason J. Antiglycation activity of Vaccinium spp. (Ericaceae) from the Sam Vander Kloet collection for the treatment of type II diabetes1. Botany 2012; 90: 401-406
  CrossrefPubMedGoogle Scholar
• 134 Jariyapamornkoon N, Yibchokanun S, Adisakwattana S. Inhibition of advanced glycation end products by red grape skin extract and its antioxidant activity. BMC Complement Altern Med 2013; 13: 1-9
  CrossrefPubMedGoogle Scholar
• 135 Shen Y, Xu Z, Sheng Z. Ability of resveratrol to inhibit advanced glycation end product formation and carbohydrate-hydrolyzing enzyme activity, and to conjugate methylglyoxal. Food Chem 2017; 216: 153-160
  CrossrefPubMedGoogle Scholar
• 136 Asumoto A, Kimoto U, Obori A. Dietary phloridzin reduces blood glucose levels and reverses Sglt1 expression in the small intestine in streptozotocin-induced diabetic mice. J Agric Food Chem 2009; 24: 4651-4656
  CrossrefPubMedGoogle Scholar
• 137 Zielinska D, Laparra-Llopis J, Zielinski H, Szawara-Nowak D, Giménez-Bastida J. Role of apple phytochemicals, phloretin and phloridzin, in modulating processes related to intestinal inflammation. Nutrients 2019; 11: 1-14
  CrossrefPubMedGoogle Scholar
• 138 Cao X, Xia Y, Zeng M, Wang W, He Y, Liu J. Caffeic acid inhibits the formation of advanced glycation endproducts (AGEs) and mitigates the AGEs-induced oxidative stress and inflammation reaction in human umbilical vein endothelial cells (HUVECs). Chem Biodivers 2019; 16: 1-20
  PubMedGoogle Scholar
• 139 Raghu G, Jakhotia S, Yadagiri Reddy P, Kumar PA, Bhanuprakash Reddy G. Ellagic acid inhibits non-enzymatic glycation and prevents proteinuria in diabetic rats. Food Funct 2016; 7: 1574-1583
  CrossrefPubMedGoogle Scholar
• 140 Muthenna P, Akileshwari C, Reddy B. Ellagic acid, a new antiglycating agent: Its inhibition of N ε-(carboxymethyl)lysine. Biochem J 2012; 442: 221-230
  CrossrefPubMedGoogle Scholar
• 141 Huang S, Hsu C, Chuang H, Shih P, Wu C, Yen G. Inhibitory effect of vanillic acid on methylglyoxal-mediated glycation in apoptotic Neuro-2A cells. Neurotoxicology 2008; 29: 1016-1022
  CrossrefPubMedGoogle Scholar
• 142 Kim J, Jeong I, Kim C, Lee Y, Kim J, Kim J. Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. Arch Pharm Res 2011; 34: 495-500
  CrossrefPubMedGoogle Scholar
• 143 Sompong W, Cheng H, Adisakwattana S. Ferulic acid prevents methylglyoxal-induced protein glycation, DNA damage, and apoptosis in pancreatic β-cells. J Physiol Biochem 2017; 73: 121-131
  CrossrefPubMedGoogle Scholar
• 144 Ramu R, Shirahatti P, Zameer F, Ranganatha L, Nagendra Prasad MN. Inhibitory effect of banana (Musa sp. var. Nanjangud rasa bale) flower extract and its constituents umbelliferone and lupeol on α-glucosidase, aldose reductase and glycation at multiple stages. South African J Bot 2014; 95: 54-63
  CrossrefPubMedGoogle Scholar
• 145 Shay J, Elbaz H, Lee I, Zielske S, Malek M, Hüttemann M. Molecular mechanisms and therapeutic effects of (−)-epicatechin and other polyphenols in cancer, inflammation, diabetes, and neurodegeneration. Oxid Med Cell Longev 2015; 2015: 1-13
  CrossrefPubMedGoogle Scholar
• 146 Wu X, Zhang G, Hu X, Pan J, Liao Y, Ding H. Inhibitory effect of epicatechin gallate on protein glycation. Food Res Int 2019; 122: 230-240
  CrossrefPubMedGoogle Scholar
• 147 Rasheed Z, Anbazhagan A, Akhtar N, Ramamurthy S, Voss F, Haqqi T. Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-α and matrix metalloproteinase-13 in human chondrocytes. Arthritis Res Ther 2009; 11: 1-13
  CrossrefPubMedGoogle Scholar
• 148 Zhou Q, Cheng K, Gong J, Li E, Wang M. Apigenin and its methylglyoxal-adduct inhibit advanced glycation endproducts-induced oxidative stress and inflammation in endothelial cells. Biochem Pharmacol 2019; 166: 231-241
  CrossrefPubMedGoogle Scholar
• 149 Pari L, Srinivasan S. Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Biomed Pharmacother 2010; 64: 477-481
  CrossrefPubMedGoogle Scholar
• 150 Peng X, Zheng Z, Cheng K, Shan F, Ren G, Chen F, Wang M. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. Food Chem 2008; 106: 475-481
  CrossrefPubMedGoogle Scholar
• 151 Liu J, Yang Z, Cheng Y, Wu Q, He Y, Li Q, Cao X. Eriodictyol and naringenin inhibit the formation of AGEs: an in vitro and molecular interaction study. J Mol Recognit 2020; 33: 1-7
  PubMedGoogle Scholar
• 152 Zhang X, Song Y, Han X, Feng L, Wang R, Zhang M, Zhu M, Jia X, Hu S. Liquiritin attenuates advanced glycation endproducts-induced endothelial dysfunction via RAGE/NF-κB pathway in human umbilical vein endothelial cells. Mol Cell Biochem 2013; 374: 191-201
  CrossrefPubMedGoogle Scholar
• 153 Zhang Z, Sethiel M, Shen W, Liao S, Zou Y. Hyperoside downregulates the receptor for advanced glycation endproducts (RAGE) and promotes proliferation in ECV304 cells via the c-Jun N-terminal kinases (JNK) pathway following stimulation by advanced glycation end-products in vitro . Int J Mol Sci 2013; 14: 22697-22707
  CrossrefPubMedGoogle Scholar
• 154 Urios P, Grigorova-Borsos AM, Sternberg M. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure. Eur J Nutr 2007; 46: 139-146
  CrossrefPubMedGoogle Scholar
• 155 Li Y, Ding Y. Minireview: therapeutic potential of myricetin in diabetes mellitus. Food Sci Hum Wellness 2012; 1: 19-25
  CrossrefPubMedGoogle Scholar
• 156 Thilavech T, Ngamukote S, Belobrajdic D, Abeywardena M, Adisakwattana S. Cyanidin-3-rutinoside attenuates methylglyoxal-induced protein glycation and DNA damage via carbonyl trapping ability and scavenging reactive oxygen species. BMC Complement Altern Med 2016; 16: 1-10
  CrossrefPubMedGoogle Scholar
• 157 Costantino S, Paneni F, Lüscher T, Cosentino F. Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. Int J Cardiol 2016; 203: 702-707
  CrossrefPubMedGoogle Scholar
• 158 Liu W, Cai A, Carley R, Rocchio R, Petrovas Z, Chartier C, Meng X, Su J, Cho B, Dain J, Ma H, Seeram N. Bioactive anthraquinones found in plant foods interact with human serum albumin and inhibit the formation of advanced glycation endproducts. J Food Bioact 2018; 4: 130-138
  PubMedGoogle Scholar
• 159 Btissam R, Rajae R, Amina A, Brigitte V, Mohamed N. In vitro study of anti-glycation and radical scavenging activities of the essential oils of three plants from Morocco: Origanum compactum, Rosmarinus officinalis and Pelargonium asperum . Pharmacogn J 2015; 7: 124-135
  CrossrefPubMedGoogle Scholar
• 160 Zhou P, Xie W, He S, Sun Y, Meng X, Sun G, Sun X. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis. Cells 2019; 8: 204
  CrossrefPubMedGoogle Scholar
• 161 Ding H, Ni M, Zhang G, Liao Y, Hu X, Zhang Y, Gong D. The inhibition of oleanolic acid on protein non-enzymatic glycation. LWT Food Sci Technol 2020; 125: 109253
  CrossrefPubMedGoogle Scholar
• 162 Yin M. Inhibitory effects and actions of pentacyclic triterpenes upon glycation. Biomed 2015; 5: 1-8
  CrossrefPubMedGoogle Scholar
• 163 Hao M, Li S, Sun C, Jingyu-Xu. Lin Y, Liu KX, Wang L, Li C, Zhou Q, Du J, Li H. Amelioration effects of berberine on diabetic microendothelial injury model by the combination of high glucose and advanced glycation end products in vitro . Eur J Pharmacol 2011; 654: 320-325
  CrossrefPubMedGoogle Scholar